Ifn-γ and chemokine-related genes may be the core mechanism of the combination, and the expression of these genes is correlated with tumour regression, so the Ifn-γ signature may be useful for the selection of benefits patients in clinical trials. This evidence concerns the gene IFNG and neoplasm.